ClinicalTrials.gg
CompletedNCT03051685Updated Feb 13, 2018

Bioavailability of DFN-15 at 3 Different Doses vs. Comparator and to Determine Dose-proportionality of DFN-15 in Fasting Healthy Adults

A Phase 1 interventional study of DFN-15 Dose 1 and DFN-15 Dose 2 in Healthy, sponsored by Dr. Reddy's Laboratories Limited. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-02-13.

Sponsored by Dr. Reddy's Laboratories Limited · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Aug 2015, 11 years 3 months ago, and no results have been posted to the registry.
  • Registered 1 year 6 months after the study started (first participant enrolled Jul 2015, registered Feb 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Crossover study to compare the BA of DFN-15 at 3 different doses versus the comparator to determine dose-proportionality of DFN-15 in healthy volunteers under fasting conditions

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Dr. Reddy's Laboratories Limited is the lead sponsor of 224 studies on the registry; 2 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 11 (85%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects were male or female, at least 18 years of age but not older than 45 years of age. The main inclusion criteria were:

  1. non- or ex-smokers
  2. (BMI) ≥18.50 kg/m2 and \<30.00 kg/m2
  3. no abnormality found in the 12-lead performed at study entry
  4. negative pregnancy test for female subjects
  5. healthy according to medical history, complete physical examination (including vital signs) and laboratory tests (general biochemistry, hematology, urinalysis, and coagulation)
  6. Fecal occult blood determination negative at screening

Exclusion criteria

Exclusion Criteria:

  1. Females who were pregnant or were lactating
  2. Patients who had a history of allergic reactions to non-steroidal anti-inflammatory drugs (NSAIDs), including patients in whom aspirin or other NSAIDs induce the syndrome of asthma, rhinitis, nasal polyps or Samter's triad
  3. Presence of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects
  4. History of significant gastrointestinal, liver or kidney disease that may affect drug bioavailability
  5. Presence of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease
  6. Suicidal tendency, history of or disposition to seizures, state of confusion, psychiatric diseases, neurological impairment or cognitive dysfunction that, in the opinion of the investigator, would compromise validity of , study participation and compliance or data collection
  7. Presence of out-of-range cardiac intervals and/ or morphological changes suggestive of arrhythmias or ischaemic heart disease on the screening (ECG) or other clinically significant ECG abnormalities
  8. History or current hypertension, bleeding disorders, ischaemic heart disease, stroke and/or cerebrovascular disease or renal disease
  9. History of asthma, urticaria, or allergic-type reactions after taking acetylsalicylic acid (ASA) or other NSAIDs
  10. Presence or history of gastric, duodenal or peptic ulcer or gastrointestinal bleeding
  11. Use of ASA or NSAIDs, or any product containing ASA or NSAIDs, in the previous 7 days before day 1 of this study
  12. Known presence of rare hereditary problems of galactose and /or lactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
  13. Maintenance therapy with any drug or significant history of drug dependency (including marijuana and medical marijuana) or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic) within 1 year
  14. Any clinically significant illness in the previous 28 days before day 1 of this study
  15. Any history of tuberculosis and/or prophylaxis for tuberculosis
  16. Positive urine screening of alcohol and/or drugs of abuse
  17. Positive results to Ag/Ab Combo, surface Antigen (HBsAG (B)) or anti Virus (HCV (C)) tests
  18. Females who were pregnant according to a positive pregnancy test
  19. Volunteers who took an product (in another clinical trial) in the previous 28 days before day 1 of this study or who had already participated in this clinical study
  20. Volunteers who donated plasma in the previous 14 days before day 1 of this study
  21. Donation of 500 mL or more of blood (American Red Cross, clinical studies, etc.) in the previous 56 days before day 1 of this study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    DFN-15 Dose 1

    Drug: DFN-15 Dose 1

  • Experimental
    DFN-15 Dose 2

    Drug: DFN-15 Dose 2

  • Experimental
    DFN-15 Dose 3

    Drug: DFN-15 Dose 3

  • Active comparator
    Active Comparator

    Drug: Active Comparator

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic (PK) parameters of DFN-15

    DFN-15 maximum Plasma Concentration (Cmax)

    Time frame: Up to 72 hours

  2. Pharmacokinetic (PK) parameters of DFN-15

    Area under the curve (AUC) 0-15 min

    Time frame: 15 minutes

  3. Pharmacokinetic (PK) parameters of DFN-15

    Area under the curve (AUC) 0-30

    Time frame: 30 minutes

  4. Pharmacokinetic (PK) parameters of DFN-15

    Area under the curve (AUC) 0-1 hour

    Time frame: 1 hour

  5. Pharmacokinetic (PK) parameters of DFN-15

    Area under the curve (AUC) 0-2 hours

    Time frame: 2 hours

  6. Pharmacokinetic (PK) parameters of DFN-15

    Area under the curve (AUC) 0-T

    Time frame: Up to 72 hours

  7. Pharmacokinetic (PK) parameters of DFN-15

    Area under the curve (AUC) 0-RefTmax

    Time frame: Up to 72 hours

  8. Pharmacokinetic (PK) parameters of DFN-15

    Area under the curve (AUC) 0-∞

    Time frame: Up to 72 hours

07

Study locations

1 site
  • Site 1
    Fargo, North Dakota 58104, United States
08

References and documents

Publications

  • Pal A, Shenoy S, Gautam A, Munjal S, Niu J, Gopalakrishnan M, Gobburru J. Pharmacokinetics of DFN-15, a Novel Oral Solution of Celecoxib, Versus Celecoxib 400-mg Capsules: A Randomized Crossover Study in Fasting Healthy Volunteers. Clin Drug Investig. 2017 Oct;37(10):937-946. doi: 10.1007/s40261-017-0548-6. PubMed 28748412 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2015 to primary completion in Aug 2015, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2017
First posted
Feb 14, 2017
StartActual
Jul 20, 2015
Primary completionActual
Aug 14, 2015
CompletionActual
Nov 10, 2015
Last update
Feb 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03051685
Responsible party
Sponsor
First posted
Feb 14, 2017
Start date
Jul 20, 2015
Primary completion
Aug 14, 2015
Completion
Nov 10, 2015
Last update
Feb 13, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion